-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Jefferies Financial Group Comments on Reneo Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:RPHM)
Jefferies Financial Group Comments on Reneo Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:RPHM)
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating) – Research analysts at Jefferies Financial Group issued their FY2027 earnings per share (EPS) estimates for Reneo Pharmaceuticals in a research note issued on Friday, January 27th. Jefferies Financial Group analyst E. Yang expects that the company will post earnings of $3.86 per share for the year. The consensus estimate for Reneo Pharmaceuticals' current full-year earnings is ($2.16) per share.
Get Reneo Pharmaceuticals alerts:Reneo Pharmaceuticals Stock Down 1.1 %
Shares of Reneo Pharmaceuticals stock opened at $2.68 on Monday. The firm has a market cap of $65.74 million, a price-to-earnings ratio of -1.35 and a beta of 0.50. Reneo Pharmaceuticals has a 52-week low of $1.79 and a 52-week high of $6.46. The company's 50-day simple moving average is $2.32 and its 200-day simple moving average is $2.91.
Reneo Pharmaceuticals (NASDAQ:RPHM – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.05.Institutional Investors Weigh In On Reneo Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in shares of Reneo Pharmaceuticals by 87.0% in the 3rd quarter. Renaissance Technologies LLC now owns 43,000 shares of the company's stock valued at $144,000 after buying an additional 20,000 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Reneo Pharmaceuticals in the third quarter valued at $62,000. Barclays PLC boosted its position in shares of Reneo Pharmaceuticals by 33.3% during the 3rd quarter. Barclays PLC now owns 71,930 shares of the company's stock worth $241,000 after purchasing an additional 17,984 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Reneo Pharmaceuticals by 76.5% during the 2nd quarter. Federated Hermes Inc. now owns 30,000 shares of the company's stock worth $80,000 after purchasing an additional 13,000 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of Reneo Pharmaceuticals in the 2nd quarter valued at about $457,000. Hedge funds and other institutional investors own 75.61% of the company's stock.
About Reneo Pharmaceuticals
(Get Rating)
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Recommended Stories
- Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- Capital One Stock: Will Subprime Borrowers Spoil the Rally?
- MarketBeat Week in Review – 1/23- 1/27
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating) – Research analysts at Jefferies Financial Group issued their FY2027 earnings per share (EPS) estimates for Reneo Pharmaceuticals in a research note issued on Friday, January 27th. Jefferies Financial Group analyst E. Yang expects that the company will post earnings of $3.86 per share for the year. The consensus estimate for Reneo Pharmaceuticals' current full-year earnings is ($2.16) per share.
Reneo Pharmicals, Inc.(纳斯达克股票代码:RPHM — 获取评级)——杰富瑞金融集团的研究分析师在1月27日星期五发布的一份研究报告中发布了对Reneo Pharmicals的 FY2027 每股收益(EPS)估计。杰富瑞金融集团分析师E. Yang预计,该公司今年将公布每股收益3.86美元。Reneo Pharmaceuticals目前全年收益的共识估计为每股收益(2.16美元)。
Reneo Pharmaceuticals Stock Down 1.1 %
Reneo 制药股价下跌1.1%
Shares of Reneo Pharmaceuticals stock opened at $2.68 on Monday. The firm has a market cap of $65.74 million, a price-to-earnings ratio of -1.35 and a beta of 0.50. Reneo Pharmaceuticals has a 52-week low of $1.79 and a 52-week high of $6.46. The company's 50-day simple moving average is $2.32 and its 200-day simple moving average is $2.91.
周一,Reneo Pharmicals股票开盘价为2.68美元。该公司的市值为6,574万美元,市盈率为-1.35,beta值为0.50。Reneo Pharmicals的52周低点为1.79美元,创52周高点6.46美元。该公司的50天简单移动平均线为2.32美元,其200天简单移动平均线为2.91美元。
Institutional Investors Weigh In On Reneo Pharmaceuticals
机构投资者对Reneo Pharmicals的看法
A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in shares of Reneo Pharmaceuticals by 87.0% in the 3rd quarter. Renaissance Technologies LLC now owns 43,000 shares of the company's stock valued at $144,000 after buying an additional 20,000 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Reneo Pharmaceuticals in the third quarter valued at $62,000. Barclays PLC boosted its position in shares of Reneo Pharmaceuticals by 33.3% during the 3rd quarter. Barclays PLC now owns 71,930 shares of the company's stock worth $241,000 after purchasing an additional 17,984 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Reneo Pharmaceuticals by 76.5% during the 2nd quarter. Federated Hermes Inc. now owns 30,000 shares of the company's stock worth $80,000 after purchasing an additional 13,000 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of Reneo Pharmaceuticals in the 2nd quarter valued at about $457,000. Hedge funds and other institutional investors own 75.61% of the company's stock.
最近,许多机构投资者增加了或减少了在该业务中的股份。文艺复兴科技有限责任公司在第三季度将其持有的Reneo Pharmicals的股票增加了87.0%。Renaissance Technologies LLC在此期间又购买了2万股股票后,现在拥有该公司43,000股股票,价值14.4万美元。Dimensional Fund Advisors LP在第三季度收购了价值62,000美元的Reneo Pharmicals的新巴克莱集团在第三季度将其在Reneo Pharmicals的股票头寸提高了33.3%。巴克莱集团在上个季度又购买了17,984股股票后,现在拥有该公司71,930股股票,价值24.1万美元。联邦爱马仕公司在第二季度将其在Reneo Pharmicals的股份增长了76.5%。Federated Hermes Inc.在此期间又购买了13,000股股票后,现在拥有该公司价值8万美元的3万股股票。最后,Citadel Advisors LLC在第二季度收购了Reneo Pharmicals股票的新头寸,价值约为45.7万美元。对冲基金和其他机构投资者拥有该公司75.61%的股票。
About Reneo Pharmaceuticals
关于 Reneo 制药
(Get Rating)
(获取评分)
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Reneo Pharmicals, Inc是一家处于临床阶段的制药公司,专注于罕见遗传线粒体疾病患者的疗法的开发和商业化。其主要候选产品是 REN001,这是一种强效的选择性过氧化物酶体增殖物激活受体 delta 的激动剂,正在临床开发用于遗传线粒体疾病,包括原发性线粒体肌病和长链脂肪酸氧化障碍。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- Capital One Stock: Will Subprime Borrowers Spoil the Rally?
- MarketBeat Week in Review – 1/23- 1/27
- 免费获取 StockNews.com 关于 Reneo Pharmicals(RPHM)的研究报告的副本
- Yext A.I. 搜索平台能否推动2023年的增长?
- Cassava Sciences 股票被低估了 124 美元的目标价?
- Constellation Brands:消费者在向下交易铁路饮料吗?
- Capital One 股票:次级贷款借款人会破坏涨势吗?
- MarketBeat Week 回顾 — 1/23-1/27
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收Reneo Pharmicals每日的新闻和收视率 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Reneo Pharmicals及相关公司最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧